3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Hematologic Neoplasms
1
Interventions
talquetamab
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ivosidenib
1
ipatasertib
1
fedratinib
1
erdafitinib
1
enasidenib
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
adavosertib
1
X-Rays
1
Trastuzumab
1
Sunitinib
1
Specimen Handling
1
PF-05280014
1
Ontruzant
1
Ogivri
1
Nuclear Medicine Department, Hospital
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Hematologic Neoplasms
×
fedratinib
×
Clear all
NCT01437787
2025-03-05
JAKARTA
Bristol-Myers Squibb
Phase 3
Completed
289 enrolled
1 FDA